“A new global mpox vaccine stockpile is set to begin operations later this month, creating a long-term mechanism to help ensure that countries facing mpox outbreaks have rapid and equitable access to vaccines.

Like existing global emergency stockpiles for yellow fever, meningitis, Ebola and cholera vaccines, the mpox stockpile will be available to any country that needs it. However, because supplies are limited and must be distributed equitably, it is designed primarily for emergency outbreak response.

Countries eligible for Gavi support receive stockpiled vaccines free of charge. Wealthier countries can access the stockpile just as quickly, but these countries must subsequently reimburse the cost of the vaccines.”

From Gavi.

“In 2025, 90% of infants globally – or nearly 116 million – received at least one dose of a diphtheria, tetanus and pertussis (DTP) vaccine, and 85% – or 110 million – completed the full three-dose series, according to the annual WHO-UNICEF Estimates of National Immunization Coverage (WUENIC) released today.

While both indicators rose by one percentage point from the previous year, global coverage remains one point below 2019 levels – hovering within the same narrow range since 2009.

According to the data, an estimated 13.5 million 'zero-dose' children did not receive a single vaccine in their first year during 2025. While these represent nearly 750 000 fewer children than the previous year, progress is offset by a rising number of children who start the schedule and do not complete it. Most of these children live in countries where national immunization programmes receive support from Gavi, the Vaccine Alliance.”

From World Health Organization.

“Vaccines that do not need to be kept cool in a fridge have been successfully trialled in patients for the first time, say UK scientists.

Currently, most vaccines need to be refrigerated or frozen – but around half are wasted each year, mainly because they become unusable after getting too hot or too cold.

In the trial, which involved 60 volunteers, company Stablepharma converted a liquid tetanus-diphtheria vaccine into a 'fridge-free' version by keeping it as a dry powder for a year at room temperature before mixing it with water and injecting it.”

From BBC.

“The Food and Drug Administration approved Moderna’s mRNA-based flu vaccine Wednesday for adults ages 50 and older, clearing the first shot of its kind after a review process that nearly collapsed in February.

The vaccine, called mFlusiva, uses the same messenger RNA technology as Moderna’s Covid-19 shots. It could reach pharmacies in time for the coming flu season, which typically starts in the fall…

Traditional flu shots are grown in chicken eggs, a process that takes about six months and forces manufacturers to guess months in advance which strains will circulate. Moderna’s mRNA shot can be made in as little as two to three months, meaning it could better match the actual virus once flu season arrives…

In a study of more than 40,000 adults, mFlusiva cut the risk of flu by 26.6% compared with a standard-dose vaccine. That reduction was 47.9% against flu severe enough to send patients to the hospital or urgent care.”

From Wall Street Journal.